Literature DB >> 28039162

Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma.

Theodore S Nowicki1, Ryan Akiyama1, Rong Rong Huang2, I Peter Shintaku2, Xiaoyan Wang3,4, Paul C Tumeh5,6,7, Arun Singh8, Bartosz Chmielowski9, Christopher Denny1,7, Noah Federman1,7,10, Antoni Ribas11,7,8,9.   

Abstract

Tumors expressing programmed death ligand 1 (PD-L1) interact with the corresponding negative-signal generating immune receptor on the surface of CD8 T cells, PD-1, thereby suppressing antitumor activity. Therapeutics blocking this interaction have shown promise in various cancers by restoring functional antitumor T-cell activity. We explored the degree of PD-L1, PD-1, and CD8 expression in a retrospective analysis of 29 clinical synovial sarcoma samples. Quantitative immunohistochemistry and multiplex immunofluorescence were used to determine relative quantification of CD8+ and PD-1+ T cells and PD-L1 expression within the intratumor area and the interface between the tumor and the surrounding nontumor tissue (i.e., invasive margin), and colocalization of these factors, respectively. PD-L1, PD-1, and CD8 cell densities in the tumor-invasive margins were significantly higher in the metastatic tumors than the primary tumors (P < 0.01), and PD-L1, PD-1, and CD8 cell densities were all significantly positively correlated with one other (P < 0.0001). PD-1 cell density in the tumor-invasive margin was significantly associated with worse progression-free survival. Multiplex immunofluorescence demonstrated coexpression of PD-1 and CD8 on lymphocytes within the invasive margin, as well as relative proximity between PD-1+ CD8 cells and PD-L1+ tumor cells. Our results provide a preclinical rationale for screening of patients with synovial sarcoma for the colocalization of CD8, PD-1, and PD-L1, which may be a marker for response to PD-1 blockade therapy. Cancer Immunol Res; 5(2); 118-26. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28039162      PMCID: PMC5290092          DOI: 10.1158/2326-6066.CIR-16-0148

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  36 in total

1.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.

Authors:  Stefani Spranger; Riyue Bao; Thomas F Gajewski
Journal:  Nature       Date:  2015-05-11       Impact factor: 49.962

Review 2.  Synovial sarcoma: defining features and diagnostic evolution.

Authors:  Khin Thway; Cyril Fisher
Journal:  Ann Diagn Pathol       Date:  2014-10-13       Impact factor: 2.090

3.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

4.  Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation.

Authors:  Tobias Bald; Jennifer Landsberg; Dorys Lopez-Ramos; Marcel Renn; Nicole Glodde; Philipp Jansen; Evelyn Gaffal; Julia Steitz; Rene Tolba; Ulrich Kalinke; Andreas Limmer; Göran Jönsson; Michael Hölzel; Thomas Tüting
Journal:  Cancer Discov       Date:  2014-03-03       Impact factor: 39.397

5.  Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

Authors:  Caroline Robert; Antoni Ribas; Jedd D Wolchok; F Stephen Hodi; Omid Hamid; Richard Kefford; Jeffrey S Weber; Anthony M Joshua; Wen-Jen Hwu; Tara C Gangadhar; Amita Patnaik; Roxana Dronca; Hassane Zarour; Richard W Joseph; Peter Boasberg; Bartosz Chmielowski; Christine Mateus; Michael A Postow; Kevin Gergich; Jeroen Elassaiss-Schaap; Xiaoyun Nicole Li; Robert Iannone; Scot W Ebbinghaus; S Peter Kang; Adil Daud
Journal:  Lancet       Date:  2014-07-15       Impact factor: 79.321

6.  The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer.

Authors:  S Muenst; S D Soysal; F Gao; E C Obermann; D Oertli; W E Gillanders
Journal:  Breast Cancer Res Treat       Date:  2013-06-12       Impact factor: 4.872

7.  PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Authors:  Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

8.  Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.

Authors:  Silvia Darb-Esfahani; Catarina Alisa Kunze; Hagen Kulbe; Jalid Sehouli; Stephan Wienert; Judith Lindner; Jan Budczies; Michael Bockmayr; Manfred Dietel; Carsten Denkert; Ioana Braicu; Korinna Jöhrens
Journal:  Oncotarget       Date:  2016-01-12

9.  Accumulation of CD5+CD19+ B lymphocytes expressing PD-1 and PD-1L in hypertrophied pharyngeal tonsils.

Authors:  Paulina Wlasiuk; Artur Niedzielski; Katarzyna Skorka; Agnieszka Karczmarczyk; Joanna Zaleska; Malgorzata Zajac; Maciej Putowski; Elzbieta Pac-Kozuchowska; Krzysztof Giannopoulos
Journal:  Clin Exp Med       Date:  2015-08-29       Impact factor: 3.984

10.  Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.

Authors:  Brian T Fife; Kristen E Pauken; Todd N Eagar; Takashi Obu; Jenny Wu; Qizhi Tang; Miyuki Azuma; Matthew F Krummel; Jeffrey A Bluestone
Journal:  Nat Immunol       Date:  2009-09-27       Impact factor: 25.606

View more
  26 in total

1.  A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.

Authors:  Richard D Kim; Vincent Chung; Olatunji B Alese; Bassell F El-Rayes; Daneng Li; Taymeyah E Al-Toubah; Michael J Schell; Jun-Min Zhou; Amit Mahipal; Baek Hui Kim; Dae Won Kim
Journal:  JAMA Oncol       Date:  2020-06-01       Impact factor: 31.777

2.  A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab.

Authors:  Theodore S Nowicki; Beata Berent-Maoz; Gardenia Cheung-Lau; Rong Rong Huang; Xiaoyan Wang; Jennifer Tsoi; Paula Kaplan-Lefko; Paula Cabrera; Justin Tran; Jia Pang; Mignonette Macabali; Ivan Perez Garcilazo; Ignacio Baselga Carretero; Anusha Kalbasi; Alistair J Cochran; Catherine S Grasso; Siwen Hu-Lieskovan; Bartosz Chmielowski; Begoña Comin-Anduix; Arun Singh; Antoni Ribas
Journal:  Clin Cancer Res       Date:  2018-12-20       Impact factor: 12.531

3.  Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy.

Authors:  Emily Z Keung; Jen-Wei Tsai; Ali M Ali; Janice N Cormier; Andrew J Bishop; B Ashleigh Guadagnolo; Keila E Torres; Neeta Somaiah; Kelly K Hunt; Jennifer A Wargo; Alexander J Lazar; Wei-Lien Wang; Christina L Roland
Journal:  Oncoimmunology       Date:  2017-10-31       Impact factor: 8.110

4.  Identification and Validation of Pyroptosis-Related lncRNA Signature and Its Correlation with Immune Landscape in Soft Tissue Sarcomas.

Authors:  Zhengjun Lin; Yiting Xu; Xianghong Zhang; Jia Wan; Tao Zheng; Hongxuan Chen; Shijie Chen; Tang Liu
Journal:  Int J Gen Med       Date:  2021-11-16

Review 5.  The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy.

Authors:  Daniela Bruni; Helen K Angell; Jérôme Galon
Journal:  Nat Rev Cancer       Date:  2020-08-04       Impact factor: 60.716

6.  A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas.

Authors:  Thomas G P Grünewald; Thomas Knösel; Martin F Orth; Veit Leonhard Buecklein; Eric Kampmann; Marion Subklewe; Elfriede Noessner; Florencia Cidre-Aranaz; Laura Romero-Pérez; Fabienne Sophie Wehweck; Lars Lindner; Rolf Issels; Thomas Kirchner; Annelore Altendorf-Hofmann
Journal:  Cancer Immunol Immunother       Date:  2020-03-28       Impact factor: 6.968

7.  Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab.

Authors:  Emily Z Keung; Melissa Burgess; Ruth Salazar; Edwin R Parra; Jaime Rodrigues-Canales; Vanessa Bolejack; Brian A Van Tine; Scott M Schuetze; Steven Attia; Richard F Riedel; James Hu; Scott H Okuno; Dennis A Priebat; Sujana Movva; Lara E Davis; Damon R Reed; Alexandre Reuben; Christina L Roland; Denise Reinke; Alexander J Lazar; Wei-Lien Wang; Jennifer A Wargo; Hussein A Tawbi
Journal:  Clin Cancer Res       Date:  2020-01-03       Impact factor: 12.531

Review 8.  Targeting cancer testis antigens in synovial sarcoma.

Authors:  Geoffrey Mitchell; Seth M Pollack; Michael J Wagner
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

9.  Multi-Omics Perspective Reveals the Different Patterns of Tumor Immune Microenvironment Based on Programmed Death Ligand 1 (PD-L1) Expression and Predictor of Responses to Immune Checkpoint Blockade across Pan-Cancer.

Authors:  Kaitang Huang; Meiling Hu; Jiayun Chen; Jinfen Wei; Jingxin Qin; Shudai Lin; Hongli Du
Journal:  Int J Mol Sci       Date:  2021-05-13       Impact factor: 5.923

10.  Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent.

Authors:  Anke E M van Erp; Yvonne M H Versleijen-Jonkers; Melissa H S Hillebrandt-Roeffen; Laurens van Houdt; Mark A J Gorris; Laura S van Dam; Thomas Mentzel; Marije E Weidema; C Dilara Savci-Heijink; Ingrid M E Desar; Hans H M Merks; Max M van Noesel; Janet Shipley; Winette T A van der Graaf; Uta E Flucke; Friederike A G Meyer-Wentrup
Journal:  Oncotarget       Date:  2017-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.